Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
EJNMMI Research
Published in: EJNMMI Research 1/2017

Open Access 01-12-2017 | Original research

Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects

Authors: Huailei Jiang, Nicholas R. Schmit, Alex R. Koenen, Aditya Bansal, Mukesh K. Pandey, Robert B. Glynn, Bradley J. Kemp, Kera L. Delaney, Angela Dispenzieri, Jamie N. Bakkum-Gamez, Kah-Whye Peng, Stephen J. Russell, Tina M. Gunderson, Val J. Lowe, Timothy R. DeGrado

Published in: EJNMMI Research | Issue 1/2017

Login to get access

Abstract

Background

18F-Tetrafluoroborate (18F-TFB) is a promising iodide analog for PET imaging of thyroid cancer and sodium/iodide symporter (NIS) reporter activity in viral therapy applications. The aim of this study was to evaluate the safety, pharmacokinetics, biodistribution, and radiation dosimetry of high-specific activity 18F-TFB in healthy human subjects.

Methods

18F-TFB was synthesized with specific activity of 3.2 ± 1.3 GBq/μmol (at the end of synthesis). Dynamic and whole-body static PET/CT scans over 4 h were performed after intravenous administration of 18F-TFB (333–407 MBq) in four female and four male healthy volunteers (35 ± 11 years old). Samples of venous blood and urine were collected over the imaging period and analyzed by ion-chromatography HPLC to determine tracer stability. Vital signs and clinical laboratory safety assays were measured to evaluate safety.

Results

18F-TFB administration was well tolerated with no significant findings on vital signs and no clinically meaningful changes in clinical laboratory assays. Left-ventricular blood pool time-activity curves showed a multi-phasic blood clearance of 18F-radioactivity with the two rapid clearance phases over the first 20 min, followed by a slower clearance phase. HPLC analysis showed insignificant 18F-labeled metabolites in the blood and urine over the length of the study (4 h). High uptakes were seen in the thyroid, stomach, salivary glands, and bladder. Urinary clearance of 18F-TFB was prominent. Metabolic stability was evidenced by low accumulation of 18F-radioactivity in the bone. Effective doses were 0.036 mSv/MBq in males and 0.064 mSv/MBq in females (p = 0.08, not significant).

Conclusions

This initial study in healthy human subjects showed 18F-TFB was safe and distributed in the human body similar to other iodide analogs. These data support further translational studies with 18F-TFB as NIS gene reporter and imaging biomarker for thyroid cancer and other disease processes that import iodide.
Appendix
Available only for authorised users
Literature
1.
Chung JK. Sodium iodide symporter: its role in nuclear medicine. J Nucl Med. 2002;43:1188–200.PubMed
2.
Penheiter AR, Russell SJ, Carlson SK. The sodium iodide symporter (NIS) as an imaging reporter for gene, viral, and cell-based therapies. Curr Gene Ther. 2012;12:33–47.CrossRefPubMedPubMedCentral
3.
4.
Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature. 1996;379:458–60.CrossRefPubMed
5.
Eskandari S, Loo DD, Dai G, Levy O, Wright EM, Carrasco N. Thyroid Na+/I− symporter: mechanism, stoichiometry, and specificity. J Biol Chem. 1997;272:27230–8.CrossRefPubMed
6.
Miller A, Russell SJ. The use of the NIS reporter gene for optimizing oncolytic virotherapy. Expert Opin on Biol Ther. 2016;16:15–32.CrossRef
7.
Jauregui-Osoro M, Sunassee K, Weeks AJ, Berry DJ, Paul RL, Cleij M, et al. Synthesis and biological evaluation of F-18 tetrafluoroborate: a PET imaging agent for thyroid disease and reporter gene imaging of the sodium/iodide symporter. Eur J Nucl Med Mol Imaging. 2010;37:2108–16.CrossRefPubMedPubMedCentral
8.
Weeks AJ, Jauregui-Osoro M, Cleij M, Blower JE, Ballinger JR, Blower PJ. Evaluation of F-18 -tetrafluoroborate as a potential PET imaging agent for the human sodium/iodide symporter in a new colon carcinoma cell line, HCT116, expressing hNIS. Nucl Med Comm. 2011;32:98–105.CrossRef
9.
Marti-Climent JM, Collantes M, Jauregui-Osoro M, Quincoces G, Prieto E, Bilbao I, et al. Radiation dosimetry and biodistribution in non-human primates of the sodium/iodide PET ligand F-18-tetrafluoroborate. EJNMMI Res. 2015;5:70.CrossRefPubMedPubMedCentral
10.
Youn H, Jeong JM, Chung J-KA. New PET probe, F-18-tetrafluoroborate, for the sodium/iodide symporter: possible impacts on nuclear medicine. Eur J Nucl Med Mol Imaging. 2010;37:2105–7.CrossRefPubMed
11.
O' Doherty J, Jauregui-Osoro M, Brothwood T, Szyszko T, Marsden P, O'Doherty M, et al. 18F-tetrafluoroborate (18F-TFB), a PET probe for imaging sodium-iodide symporter expression: whole-body biodistribution, safety and radiation dosimetry in thyroid cancer patients. J Nucl Med. 2017;58:1666–71.CrossRef
12.
Jiang H, Bansal A, Pandey MK, Peng KW, Suksanpaisan L, Russell SJ, et al. Synthesis of F-18-tetrafluoroborate via radiofluorination of boron trifluoride and evaluation in a murine C6-glioma tumor model. J Nucl Med. 2016;57:1454–9.CrossRefPubMed
13.
Khoshnevisan A, Jauregui-Osoro M, Shaw K, Torres JB, Young JD, Ramakrishnan NK, et al. F-18 tetrafluoroborate as a PET tracer for the sodium/iodide symporter: the importance of specific activity. EJNMMI Res. 2016;6:34.CrossRefPubMedPubMedCentral
14.
Jiang H, Bansal A, Pandey M, Peng KW, Suksanpaisan L, Russell SJ, et al. Synthesis of 18F-tetrafluoroborate (18F-TFB) via radiofluorination of boron trifluoride and evaluation in a murine C6-glioma tumor model. J Nucl Med. 2016;57:S2721a.
15.
Schleien B, Slaback LA Jr, Birky BK. Handbook of health physics and radiological health. 3rd ed. Baltimore: Williams and Wilkins; 1998. p. 12–23.
16.
Tazebay UH, Wapnir IL, Levy O, Dohan O, Zuckier LS, Zhao QH, et al. The mammary gland iodide transporter is expressed during lactation and in breast cancer. Nat Med. 2000;6:871–8.CrossRefPubMed
17.
Beyer SJ, Zhang X, Jimenez RE, Lee ML, Richardson AL, Huang K, et al. Microarray analysis of genes associated with cell surface NIS protein levels in breast cancer. BMC Research Notes. 2011;4:397.CrossRefPubMedPubMedCentral
18.
Chang JF, Chen PJ, Sze DY, Reid T, Bartlett D, Kirn DH, et al. Oncolytic virotherapy for advanced liver tumours. J Cell Mol Med. 2009;13:1238–47.CrossRefPubMed
19.
Aravalli RN, Belcher JD, Steer CJ. Liver-targeted gene therapy: approaches and challenges. Liver Transpl. 2015;21:718–37.CrossRefPubMed
20.
Hickey RD, Mao SA, Glorioso J, Elgilani F, Amiot B, Chen H, et al. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1. Sci Transl Med. 2016;8:349ra99.CrossRefPubMedPubMedCentral
21.
Quinn B, Dauer Z, Pandit-Taskar N, Schoeder H, Dauer LT. Radiation dosimetry of 18F-FDG PET/CT: incorporating exam-specific parameters in dose estimates. BMC Med Imaging. 2016;16:41.CrossRefPubMedPubMedCentral
22.
Mattsson S, Johansson L, Leide-Svegborn S, Liniecki J, Nosske D, Riklund KA, et al. Radiation dose to patients from radiopharmaceuticals. ICRP publication 128. Ann ICRP 44(2S), 2015.
Metadata
Title
Safety, pharmacokinetics, metabolism and radiation dosimetry of 18F-tetrafluoroborate (18F-TFB) in healthy human subjects
Authors
Huailei Jiang
Nicholas R. Schmit
Alex R. Koenen
Aditya Bansal
Mukesh K. Pandey
Robert B. Glynn
Bradley J. Kemp
Kera L. Delaney
Angela Dispenzieri
Jamie N. Bakkum-Gamez
Kah-Whye Peng
Stephen J. Russell
Tina M. Gunderson
Val J. Lowe
Timothy R. DeGrado
Publication date
01-12-2017
Publisher
Springer Berlin Heidelberg
Published in
EJNMMI Research / Issue 1/2017
Electronic ISSN: 2191-219X
DOI
https://doi.org/10.1186/s13550-017-0337-5

Other articles of this Issue 1/2017

EJNMMI Research 1/2017 Go to the issue

Preliminary research

Hepatobiliary scintigraphy may improve radioembolization treatment planning in HCC patients

Original research

[18F]-BMS-747158-02PET imaging for evaluating hepatic mitochondrial complex 1dysfunction in a mouse model of non-alcoholic fatty liver disease

Preliminary research

Semi-quantitative metabolic values on FDG PET/CT including extracardiac sites of disease as a predictor of treatment course in patients with cardiac sarcoidosis

Original research

The impact of reconstruction and scanner characterisation on the diagnostic capability of a normal database for [123I]FP-CIT SPECT imaging

Original research

Quantitative evaluation of oxygen metabolism in the intratumoral hypoxia: 18F-fluoromisonidazole and 15O-labelled gases inhalation PET

Original research

Pharmacokinetic modeling of [11C]flumazenil kinetics in the rat brain